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We thank Dora Buonfrate and colleagues for their interest in our Seminar on soil-transmitted 
helminth (STH) infections.1 We appreciate their highlighting the importance of strongyloidiasis, 
which is often overlooked because of the poor sensitivity of standard stool examinations to detect 
Strongyloides stercoralis. For this reason, we noted in the Seminar that more sensitive techniques, 
such as the Baermann stool concentration or Koga agar plate culture, are often needed to confirm 
diagnosis. We agree that more sensitive tests for S. stercoralis, including serologic assays and 
polymerase chain reaction, should be used when available. However, it is also our understanding 
that despite the increasing use of such tests, they are still not widely used as routine diagnostic tools 
in most STH-endemic areas. As an overview for clinicians and public health scientists, in both low-
income and high-income settings, our Seminar aimed to balance state-of-the-art diagnostic and 
treatment options with the often poor availability and accessibility to health services in endemic 
areas.  
 
We further agree with Buonfrate and colleagues that ivermectin is the first choice of treatment for 
strongyloidiasis. However, in endemic settings where ivermectin and thiabendazole are sometimes 
not available, data would suggest that treatment with albendazole is superior to no treatment.[2]  
 
The authors rightly underscore the clinical and public health importance of strongyloidiasis, the need 
for sensitive diagnostic tests, and the superior treatment efficacy of ivermectin. In this regard, we 
applaud the recent WHO recommendation to include ivermectin in a triple-drug regimen for 
preventive chemotherapy for lymphatic filariasis,[3] and the subsequent expansion by Merck of its 
Mectizan donation to support this recommendation.[4] In addition to hastening the elimination of 
lymphatic filariasis, the collateral benefits of this regimen against strongyloidiasis are likely to be 
substantial. However, control of strongyloidiasis worldwide will require an adequate supply of 
effective drugs as well as improved mapping of endemic areas to guide their administration. 
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